Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/10534
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- IOC - Artigos de Periódicos [12500]
Metadata
Mostrar registro completo
NOVEL RECOMBINANT BCG VACCINES: DO THE ORDINARY PLATFORMS MATTER?
Antas, Paulo R. Z | Data do documento:
2013
Autor(es)
Afiliação
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
Bacillus Calmette-Guerin (BCG) is the common name given to a family of vaccines against human tuberculosis.
Created in 1921 by the in vitro attenuation of a virulent Mycobacterium bovis in France, the BCG vaccine continues
to generate debate and confusion after nearly a century of use. Since the 1940s, significant sequence differences
among the BCG strains have been reported. In addition, relationships between the recombinant BCG vaccines used
in current clinical trials and their parental strains have been never fully delineated. In order to standardize and to
clarify the subject regarding common BCG strains used to generate those novel vaccines, a sequential emergence
of the parental strains and their matching recombinant strains was built. Hence, for a total of 16 BCG strains in
worldwide circulation, 9 have been used to sustain one or more genetic alterations, resulting in around 21 novel
recombinant BCG strains. Although it is an outstanding achievement, only 2 out of the 21 recombinant strains are
from the most immunogenic group. Systematizing the novel BCG vaccines and their parental strains may facilitate
our understanding of protection provided by BCG immunizations.
Compartilhar